| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antibody-mediated Remyelination: Relevance to Multiple Sclerosis
|
Bieber, A
|
|
2000
|
|
2_suppl |
p. S1-S5
|
artikel
|
| 2 |
Appendix: Supplement to Multiple Sclerosis Optimizing Outcomes in Multiple Sclerosis – A Consensus Initiative CME Section Posttest and Evaluation form
|
|
|
2009
|
|
2_suppl |
p. 36-39
|
artikel
|
| 3 |
Author Index
|
|
|
2018
|
|
2_suppl |
p. 1027-1066
|
artikel
|
| 4 |
Conclusions: Calls to action for improving the life of MS patients and their families
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 71-77
|
artikel
|
| 5 |
Contents
|
|
|
2018
|
|
2_suppl |
p. 1-5
|
artikel
|
| 6 |
ECTRIMS 2019 – Author Index
|
|
|
2019
|
|
2_suppl |
p. 939-974
|
artikel
|
| 7 |
ECTRIMS 2018 Committees
|
|
|
2018
|
|
2_suppl |
p. 6-7
|
artikel
|
| 8 |
ECTRIMS 2019 Committees
|
|
|
2019
|
|
2_suppl |
p. 1-2
|
artikel
|
| 9 |
ECTRIMS 2019 - ePosters
|
|
|
2019
|
|
2_suppl |
p. 806-889
|
artikel
|
| 10 |
ECTRIMS 2019 – Late Breaking News Abstracts
|
|
|
2019
|
|
2_suppl |
p. 890-938
|
artikel
|
| 11 |
ECTRIMS 2019 – Oral Presentations
|
|
|
2019
|
|
2_suppl |
p. 3-130
|
artikel
|
| 12 |
ECTRIMS 2019 - Poster Session 1
|
|
|
2019
|
|
2_suppl |
p. 131-356
|
artikel
|
| 13 |
ECTRIMS 2019 - Poster Session 2
|
|
|
2019
|
|
2_suppl |
p. 357-580
|
artikel
|
| 14 |
ECTRIMS 2019 - Poster Session 3
|
|
|
2019
|
|
2_suppl |
p. 581-805
|
artikel
|
| 15 |
Editorial
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 2-3
|
artikel
|
| 16 |
ePosters
|
|
|
2018
|
|
2_suppl |
p. 738-980
|
artikel
|
| 17 |
ESIMS - An Ongoing Clinical Trial in Secondary Progressive Multiple Sclerosis
|
Hommes, OR
|
|
2000
|
|
2_suppl |
p. S27-S32
|
artikel
|
| 18 |
High Dose IVIG in the Post Partum Period for Prevention of Exacerbations in MS
|
Haas, J
|
|
2000
|
|
2_suppl |
p. S18-S20
|
artikel
|
| 19 |
Immunoglobulins Treatment in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
|
Achiron, Anat
|
|
2000
|
|
2_suppl |
p. S6-S8
|
artikel
|
| 20 |
Introduction: Do we need multi-stakeholder colloquia in MS?
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 4-8
|
artikel
|
| 21 |
Late Breaking News Submissions
|
|
|
2018
|
|
2_suppl |
p. 981-1026
|
artikel
|
| 22 |
Mechanisms of Action of Intravenous Immunoglobulin (IVIG)
|
Kazatchkine, Michel D
|
|
2000
|
|
2_suppl |
p. S24-S26
|
artikel
|
| 23 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 17-28
|
artikel
|
| 24 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 29-40
|
artikel
|
| 25 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 53-64
|
artikel
|
| 26 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for France
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 65-77
|
artikel
|
| 27 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 78-90
|
artikel
|
| 28 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 91-103
|
artikel
|
| 29 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 104-116
|
artikel
|
| 30 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 130-142
|
artikel
|
| 31 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 143-154
|
artikel
|
| 32 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 155-165
|
artikel
|
| 33 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 166-178
|
artikel
|
| 34 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 179-191
|
artikel
|
| 35 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 192-203
|
artikel
|
| 36 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 117-129
|
artikel
|
| 37 |
New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 204-216
|
artikel
|
| 38 |
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 41-52
|
artikel
|
| 39 |
Open Discussion following the Presentations on IVIG
|
|
|
2000
|
|
2_suppl |
p. S33
|
artikel
|
| 40 |
Optimizing Outcomes in Multiple Sclerosis – A Consensus Initiative
|
Coyle, P
|
|
2009
|
|
2_suppl |
p. 5-35
|
artikel
|
| 41 |
Optimizing Outcomes in Multiple Sclerosis – A Consensus Initiative
|
Coyle, Patricia K.
|
|
2009
|
|
2_suppl |
p. 1-4
|
artikel
|
| 42 |
Oral Presentations
|
|
|
2007
|
|
2_suppl |
p. 7-273
|
artikel
|
| 43 |
Oral presentations
|
|
|
2018
|
|
2_suppl |
p. 8-120
|
artikel
|
| 44 |
Poster Session 1
|
|
|
2018
|
|
2_suppl |
p. 121-327
|
artikel
|
| 45 |
Poster Session 3
|
|
|
2018
|
|
2_suppl |
p. 530-737
|
artikel
|
| 46 |
Poster Session 2
|
|
|
2018
|
|
2_suppl |
p. 328-529
|
artikel
|
| 47 |
Preface
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 2-3
|
artikel
|
| 48 |
The Austrian Immunoglobulin in MS (AIMS) Study: Final Analysis
|
Strasser-Fuchs, Siegrid
|
|
2000
|
|
2_suppl |
p. S9-S13
|
artikel
|
| 49 |
The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms
|
Kobelt, Gisela
|
|
2017
|
|
2_suppl |
p. 4-16
|
artikel
|
| 50 |
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 18-33
|
artikel
|
| 51 |
The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis
|
Sørensen, Per Soelberg
|
|
2000
|
|
2_suppl |
p. S14-S17
|
artikel
|
| 52 |
The importance of a multi-disciplinary perspective and patient activation programmes in MS management
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 34-46
|
artikel
|
| 53 |
The patient’s perspective: How to create awareness for improving access to care and treatment of MS patients?
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 9-17
|
artikel
|
| 54 |
The payer’s perspective: What is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 60-70
|
artikel
|
| 55 |
The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?
|
Comi, Giancarlo
|
|
2016
|
|
2_suppl |
p. 47-59
|
artikel
|
| 56 |
Treatment of Chronic Progressive Multiple Sclerosis with Intravenous Immunoglobulins - interim Results on Drug Safety of an Ongoing Study
|
Poehlau, D
|
|
2000
|
|
2_suppl |
p. S21-S23
|
artikel
|
Tijdschrift beschrijving